H.C. Wainwright Keeps a Buy Rating on Minerva Neurosciences (NERV)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Minerva Neurosciences (NERV) today and set a price target of $20.00. The company’s shares closed last Friday at $2.69.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 15.7% and a 59.5% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Amag Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Minerva Neurosciences with a $20.33 average price target, a 306.6% upside from current levels. In a report issued on May 14, BTIG also initiated coverage with a Buy rating on the stock with a $23.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.22 and a one-year low of $4.01. Currently, Minerva Neurosciences has an average volume of 524.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.